1. HCM/CPR/09/43508/1 – September 2009 1 Joint Working - Why, When and How? Graham Franklin Regional Business Director, GlaxoSmithKline XXX 10 th November 2009

2. HCM/CPR/09/43508/1 – September 2009 The evolving environment Ministerial Industry Strategy Group Partnership Working Group ‘There are a number of areas where increased dialogue and partnership between the NHS and industry would deliver significant benefits for Governments, patients, industry and research’ Feb 08March 08 March 09June 08

3. HCM/CPR/09/43508/1 – September 2009 NHS-ABPI defined Joint Working Defined as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centered projects and share a commitment to successful delivery

4. HCM/CPR/09/43508/1 – September 2009 How can the NHS and the Pharmaceutical Industry find the mutual benefits of Joint Working? Additional resources Communication and IT expertise Business planning skills Appropriate use of medicines Better customer understanding Improved reputation and trust Different perspectives Creative approaches to problems Skilled personnel Better cross-sectoral working Faster NHS implementation of policy Better patient outcomes The Pharmaceutical Industry

5. HCM/CPR/09/43508/1 – September 2009 What could a Joint Working Project Look Like? Pooled resource –Mutual contribution to providing the resources to meet and address the patient need: Staff training Staff and or patient education Economic analysis Facilitation of pathway redesign Support for guideline implementation Funding of project staff requirements (administrative, clinical, analytical health economic and or management resources)

6. HCM/CPR/09/43508/1 – September 2009 Examples of Partnership Working

7. HCM/CPR/09/43508/1 – September 2009 Improving COPD Management NHS Salford and GSK NHS Salford Project Win/Win/Win Results Serves more than 216,000 patients High COPD prevalence (2.5% vs 1.4% national average) To enhance the group’s capability and capacity to appropriately manage its COPD patient population by implementing: –Treatment pathways and protocol –Health Care Professional and patient education programmes –Patient audit tools (POINTS) –Patient review Patient: Better outcomes via proactive treatment NHS: Up-skilled staff, improving quality and resource utilisation GSK: More opportunities for appropriate use of medicines Analysis ongoing – interim data indicates: –Length of hospital stay reduced from 7.4 to 6.9 days 1 –PCT hospital expenditure reduced by £167,000 1 –An estimated 255 hospital admissions were avoided 1 –430 additional patients were added to the COPD register 2 1. Data supplied by NHS Salford, 8 June 2009 2. Roberts JA and Diar Bakerly N Benchmarking COPD across an inner city PCT: one year on. Thorax (2008) (Suppl VII): A8 s12 HCM/MTP/09/43726/1, October 2009

8. HCM/CPR/09/43508/1 – September 2009 Exploring partnership opportunities further GSK contact: –Graham.c.Franklin@gsk.com – Regional Business DirectorGraham.c.Franklin@gsk.com –David.a.robinson@gsk.com – Area Business ManagerDavid.a.robinson@gsk.com –Visit the GSK Stand at London Health ’09 You can access the Joint Working Toolkit produced by the DH and ABPI on: www.dh.gov.uk

9. HCM/CPR/09/43508/1 – September 2009 9 Joint Working - Why, When and How? Graham Franklin Regional Business Director, GlaxoSmithKline XXX 10 th November 2009